Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 24;11:3726. doi: 10.1038/s41467-020-17127-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a–d PARPi pretreatment tumor growth curve (left), tumor volume growth curve (middle) and survival by Kaplan–Meier analysis (right) after randomization. a WO-2PR was from a gBRCA2 mutation carrier whose PDXs were treated with olaparib until progression. Treatment groups: (1) control (n = 3), (2) PARPi 100 mg/kg/day OG 6 days weekly (n = 5), (3) ATRi 50 mg/kg/day OG 5 days weekly (n = 5), (4) PARPi 50+ATRi 50 mg/kg/day OG 5 days weekly (n = 6). Due to progression in combination group by week 10, PARPi was increased to 75 mg/kg/day 6 days weekly. b WO-57 was from a PARPi-resistant gBRCA1 mutation carrier. Treatment groups: (1) control (n = 4), (2) PARPi 75 mg/kg/day OG 6 days weekly (n = 7), (3) ATRi 40 mg/kg/day OG 5 days weekly (n = 7), (4) Both (n = 10). c WO-58 was from a PARPi-resistant gBRCA1 mutation carrier with elevated CCNE1 copy number and protein. Treatment groups similar to (b): (1) control (n = 6), (2) PARPi (n = 6), (3) ATRi (n = 8), (4) Both (n = 9). d WO-19 was from a platinum-resistant, BRCA^WT patient with CCNE1 amplification and protein overexpression by IHC magnification ×20. Scale bar = 50 μm. Treatment groups: (1) control (n = 5), (2) carboplatin 30 mg/kg IP weekly (n = 5), (3) PARPi 75 mg/kg/day OG 5 days weekly (n = 3), (4) ATRi 50 mg/kg/day OG 5 days weekly (n = 4), (5) Both (n = 6). Tumor growth shown is mean ± SEM. Longitudinal analysis by Linear Mixed-Effects modeling with type II ANOVA and pairwise comparisons across groups. Survival is shown by Kaplan–Meier curve using the Mantel-Cox log-rank test. P values provided in Supplementary Fig. 8. e–g H&E 10× and IHC 20× with 40× insets of pCHK1(S345), γH2AX, and cleaved-caspase-3 in WO-2PR and WO-19 PDXs at 2 weeks post-randomization. In box plots, bounds of boxes show interquartile range, whiskers show maximum and minimum, center lines indicate median. One-way ANOVA followed by Tukeys multiple comparison test for (e–g) (n = 27 HPF per group n = 3 mice, 9 HPF per tumor). ****P < 0.0001, WO-2 γH2AX P = 0.0039 (top), 0.0072 (bottom), cleaved-caspase-3 P = 0.0118, WO-19 γH2AX P = 0.0082. Scale bar = 100 μm. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. Data are provided as a source data file.